Cadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin
PremiumThe FlyCadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin
19d ago
Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan
Premium
Company Announcements
Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan
24d ago
Cadrenal Therapeutics highlights data on ARIES-HM3 trial at ISHLT
Premium
The Fly
Cadrenal Therapeutics highlights data on ARIES-HM3 trial at ISHLT
3M ago
A New Cause for Concern: Cadrenal Therapeutics, Inc. Adds a New Natural and Human Disruptions Risk
PremiumCompany AnnouncementsA New Cause for Concern: Cadrenal Therapeutics, Inc. Adds a New Natural and Human Disruptions Risk
6M ago
Cadrenal Therapeutics provides Q4 corporate update
Premium
The Fly
Cadrenal Therapeutics provides Q4 corporate update
6M ago
Cadrenal Therapeutics Announces Key Executive Appointment
Premium
Company Announcements
Cadrenal Therapeutics Announces Key Executive Appointment
6M ago
Cadrenal Therapeutics highlights additional need for new VKA
PremiumThe FlyCadrenal Therapeutics highlights additional need for new VKA
12M ago
Cadrenal Therapeutics files to sell 8.85M shares of common stock for holders
Premium
The Fly
Cadrenal Therapeutics files to sell 8.85M shares of common stock for holders
1y ago
Cadrenal Therapeutics sells 4.29M shares at $1.75 in private placement
Premium
The Fly
Cadrenal Therapeutics sells 4.29M shares at $1.75 in private placement
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100